Pulmonary hypertension (PH) is a complex, multifactorial disease characterized by elevated pulmonary artery pressure. This article provides an overview of the disease's pathophysiology, diagnostic approaches, and treatment options.
PH is a hemodynamic and pathophysiological condition defined by an increase in mean pulmonary arterial pressure ≥ 25 mmHg at rest. This condition can lead to right heart failure and death if left untreated. The disease's pathophysiology involves three major processes: vasoconstriction, vascular remodeling, and thrombosis.
Diagnosing PH requires a high index of suspicion. Initial diagnostic procedures include echocardiography and right heart catheterization. Echocardiography is used to estimate pulmonary artery pressure, while right heart catheterization confirms the diagnosis. Other diagnostic tools such as computed tomography (CT), magnetic resonance imaging (MRI), and ventilation-perfusion (V/Q) scan may also be used to determine the underlying cause.
Treatment of PH is tailored based on the underlying cause, disease severity, and patient's overall health. Current therapeutic strategies aim to improve symptoms, slow disease progression, and improve survival. These include general measures (oxygen therapy, diuretics), targeted PH therapies (endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, prostacyclin analogs), and advanced therapies (atrial septostomy, lung transplantation).
In conclusion, PH is a complex disease requiring a comprehensive understanding of its pathophysiology, diagnosis, and treatment. Early recognition and prompt initiation of appropriate therapy can significantly improve patient outcomes. As healthcare professionals, it is our responsibility to stay abreast with the latest developments in the field to provide optimal care to our patients.
1.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
2.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Radiation therapy can promote amphiregulin, which increases growth of metastases
5.
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
1.
Learning from Uncommon Inherited Bleeding Disorder Presentations
2.
Essential Strategies in Hematology for Healthcare Excellence
3.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
4.
All About Ferric Gluconate – The Best Source Of Iron For Anemia
5.
Lymphomatoid Papulosis: What You Need to Know
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation